Boston Scientific PE Ratio 2010-2024 | BSX
Current and historical p/e ratio for Boston Scientific (BSX) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Boston Scientific PE ratio as of February 21, 2025 is 41.98.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Boston Scientific PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-02-21 | 104.49 | 83.59 | |
| 2024-12-31 | 89.32 | $1.25 | 71.46 |
| 2024-09-30 | 83.80 | $1.21 | 69.26 |
| 2024-06-30 | 77.01 | $1.23 | 62.61 |
| 2024-03-31 | 68.49 | $1.19 | 57.55 |
| 2023-12-31 | 57.81 | $1.07 | 54.03 |
| 2023-09-30 | 52.80 | $0.82 | 64.39 |
| 2023-06-30 | 54.09 | $0.60 | 90.15 |
| 2023-03-31 | 50.03 | $0.59 | 84.80 |
| 2022-12-31 | 46.27 | $0.45 | 102.82 |
| 2022-09-30 | 38.73 | $0.42 | 92.21 |
| 2022-06-30 | 37.27 | $0.58 | 64.26 |
| 2022-03-31 | 44.29 | $0.53 | 83.57 |
| 2021-12-31 | 42.48 | $0.69 | 61.57 |
| 2021-09-30 | 43.39 | $0.73 | 59.44 |
| 2021-06-30 | 42.76 | $0.33 | 129.58 |
| 2021-03-31 | 38.65 | $0.10 | 386.50 |
| 2020-12-31 | 35.95 | $2.70 | 13.31 |
| 2020-09-30 | 38.21 | $2.69 | 14.20 |
| 2020-06-30 | 35.11 | $2.92 | 12.02 |
| 2019-12-31 | 45.22 | $3.33 | 13.58 |
| 2019-09-30 | 40.69 | $0.77 | 52.84 |
| 2019-06-30 | 42.98 | $0.69 | 62.29 |
| 2019-03-31 | 38.38 | $0.89 | 43.12 |
| 2018-12-31 | 35.34 | $0.99 | 35.70 |
| 2020-03-31 | 32.63 | $0.93 | 35.09 |
| 2018-09-30 | 38.50 | $0.47 | 81.91 |
| 2018-06-30 | 32.70 | $0.36 | 90.83 |
| 2018-03-31 | 27.32 | $0.07 | 390.29 |
| 2017-12-31 | 24.79 | $0.07 | 354.14 |
| 2017-09-30 | 29.17 | $0.61 | 47.82 |
| 2017-06-30 | 27.72 | $0.58 | 47.79 |
| 2017-03-31 | 24.87 | $0.32 | 77.72 |
| 2016-12-31 | 21.63 | $0.26 | 83.19 |
| 2016-09-30 | 23.80 | $0.06 | 396.67 |
| 2016-06-30 | 23.37 | $-0.26 | 0.00 |
| 2016-03-31 | 18.81 | $-0.03 | 0.00 |
| 2015-12-31 | 18.44 | $-0.18 | 0.00 |
| 2015-09-30 | 16.41 | $-0.01 | 0.00 |
| 2015-06-30 | 17.70 | $0.17 | 104.12 |
| 2015-03-31 | 17.75 | $0.09 | 197.22 |
| 2014-12-31 | 13.25 | $0.19 | 69.74 |
| 2014-09-30 | 11.81 | $0.21 | 56.24 |
| 2014-06-30 | 12.77 | $0.18 | 70.94 |
| 2014-03-31 | 13.52 | $0.28 | 48.29 |
| 2013-12-31 | 12.02 | $0.22 | 54.64 |
| 2013-09-30 | 11.74 | $-0.38 | 0.00 |
| 2013-06-30 | 9.27 | $-2.77 | 0.00 |
| 2012-12-31 | 5.73 | $-2.79 | 0.00 |
| 2012-09-30 | 5.74 | $-2.76 | 0.00 |
| 2012-06-30 | 5.67 | $-2.50 | 0.00 |
| 2012-03-31 | 5.98 | $-0.02 | 0.00 |
| 2011-12-31 | 5.34 | 0 | 0.00 |
| 2013-03-31 | 7.81 | $-0.06 | 0.00 |
| 2011-09-30 | 5.91 | $0.35 | 16.89 |
| 2011-06-30 | 6.91 | $0.38 | 18.18 |
| 2011-03-31 | 7.19 | $0.34 | 21.15 |
| 2010-12-31 | 7.57 | $-0.72 | 0.00 |
| 2010-09-30 | 6.13 | $-1.58 | 0.00 |
| 2010-06-30 | 5.80 | $-1.57 | 0.00 |
| 2010-03-31 | 7.22 | $-1.53 | 0.00 |
| 2009-12-31 | 9.00 | $-0.49 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $155.488B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $230.977B | 28.52 |
| Stryker (SYK) | United States | $147.446B | 31.70 |
| EssilorLuxottica (ESLOY) | France | $140.780B | 0.00 |
| Medtronic (MDT) | Ireland | $112.764B | 16.47 |
| Lonza Group Ag (LZAGY) | Switzerland | $47.084B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.818B | 29.12 |
| GE HealthCare Technologies (GEHC) | United States | $42.113B | 20.51 |
| Agilent Technologies (A) | United States | $39.025B | 25.86 |
| ResMed (RMD) | United States | $34.189B | 26.33 |
| Terumo (TRUMY) | Japan | $26.310B | 37.41 |
| Koninklijke Philips (PHG) | Netherlands | $23.527B | 16.80 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.630B | 12.95 |
| Insulet (PODD) | United States | $20.222B | 86.57 |
| Baxter (BAX) | United States | $17.074B | 12.34 |
| Sunny Optical Technology (SNPTF) | China | $11.331B | 0.00 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.245B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.513B | 35.65 |
| Bio-Rad Laboratories (BIO) | United States | $8.001B | 27.70 |
| Demant (WILYY) | Denmark | $7.946B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.621B | 13.06 |
| Prestige Consumer Healthcare (PBH) | United States | $4.200B | 20.05 |
| ICU Medical (ICUI) | United States | $3.995B | 38.03 |
| Envista Holdings (NVST) | United States | $3.693B | 29.38 |
| Perrigo (PRGO) | Ireland | $3.443B | 10.14 |
| Haemonetics (HAE) | United States | $3.188B | 15.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.989B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.921B | 19.69 |
| QuidelOrtho (QDEL) | United States | $2.760B | 23.18 |
| LeMaitre Vascular (LMAT) | United States | $2.269B | 55.15 |
| Neogen (NEOG) | United States | $2.178B | 25.10 |
| AtriCure (ATRC) | United States | $1.914B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.484B | 25.90 |
| InMode (INMD) | Israel | $1.320B | 11.03 |
| BioLife Solutions (BLFS) | United States | $1.276B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.180B | 8.43 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.997B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.938B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.930B | 14.27 |
| Evolus (EOLS) | United States | $0.926B | 0.00 |
| CeriBell (CBLL) | United States | $0.828B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.689B | 0.00 |
| Valneva SE (VALN) | France | $0.643B | 0.00 |
| Omeros (OMER) | United States | $0.557B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.529B | 22.95 |
| Owens & Minor (OMI) | United States | $0.494B | 3.86 |
| Surmodics (SRDX) | United States | $0.492B | 0.00 |
| SNDL (SNDL) | Canada | $0.462B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.459B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.373B | 0.00 |
| ZimVie (ZIMV) | United States | $0.368B | 30.98 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.349B | 0.00 |
| Cerus (CERS) | United States | $0.323B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.321B | 58.60 |
| Viemed Healthcare (VMD) | United States | $0.310B | 29.52 |
| Sanara MedTech (SMTI) | United States | $0.309B | 0.00 |
| Quanterix (QTRX) | United States | $0.292B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.289B | 19.40 |
| Biote (BTMD) | United States | $0.260B | 5.69 |
| Canopy Growth (CGC) | Canada | $0.250B | 0.00 |
| Zynex (ZYXI) | United States | $0.236B | 49.40 |
| Sanuwave Health (SNWV) | United States | $0.231B | 3.24 |
| Brainsway (BWAY) | Israel | $0.212B | 112.80 |
| High Tide (HITI) | Canada | $0.209B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.206B | 15.39 |
| MacroGenics (MGNX) | United States | $0.181B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.174B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.163B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.160B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.140B | 17.51 |
| Jin Medical (ZJYL) | China | $0.124B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.112B | 0.00 |
| Fonar (FONR) | United States | $0.091B | 12.79 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Veru (VERU) | United States | $0.086B | 0.00 |
| InterCure (INCR) | Israel | $0.075B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.067B | 0.00 |
| Exagen (XGN) | United States | $0.067B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.063B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.058B | 30.00 |
| Apyx Medical (APYX) | United States | $0.055B | 0.00 |
| Hongchang (HCIL) | China | $0.051B | 0.00 |
| MariMed (MRMD) | United States | $0.050B | 0.00 |
| United-Guardian (UG) | United States | $0.050B | 14.22 |
| ImmuCell (ICCC) | United States | $0.045B | 0.00 |
| Modular Medical (MODD) | United States | $0.044B | 0.00 |
| INLIF (INLF) | $0.040B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.031B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Agape ATP (ATPC) | $0.004B | 0.00 | |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |